Results 101 to 110 of about 25,586 (182)

Enteric Budesonide Treatment in IgA Nephropathy. [PDF]

Kidney Int Rep
Gulati S, Chaudhary AR, Chauhan S, Saraf K, Khullar D, Jasuja S, Rathore V, Meshram HS, Rovin B.   +8 more
europepmc   +1 more source

Efficacy and Safety of Telitacicept in Posttransplant Recurrent IgA Nephropathy. [PDF]

Kidney Int Rep
Sui M, Tang D, Yu J, Li Y, Zhang L, Zeng L, Zhao W.   +6 more
europepmc   +1 more source

New Horizons in IgA Nephropathy: Approach to Current and Emerging Therapies. [PDF]

Cureus
Madhavaram SK, Srinivas S, Bhanushali SA, Kalra K.   +3 more
europepmc   +1 more source

Development of IgA nephropathy following risankizumab therapy for psoriatic arthritis: a case report. [PDF]

CEN Case Rep
Yagasaki M, Yamada K, Koshida T, Takagi M, Saeki H, Ogiwara K, Kobayashi T, Kihara M, Gohda T, Suzuki Y.   +9 more
europepmc   +1 more source

Systematic Review of IgA Nephropathy Coexisting With Alport Syndrome. [PDF]

Kidney Int Rep
Ying D, Zhang Y, Ma Y, Wei C, Fan J, Shi P, Wang M, Zhang J.   +7 more
europepmc   +1 more source

IgA Nephropathy: Epidemiology, Outcomes, and Insights for Primary Glomerulonephritides. [PDF]

J Clin Med
Jakubowska Z, Wantoch-Rekowski F, Małyszko JS, Małyszko J.   +3 more
europepmc   +1 more source

Anti-CD38 Therapy With Daratumumab in High-Risk IgA Nephropathy. [PDF]

Kidney Int Rep
Poux M, De Vriese AS, Cohen C, Duong Van Huyen JP, Daugas E, Jolivot A, Joher N, Matignon M, Hertig A, El Karoui K.   +9 more
europepmc   +1 more source

Poly-IgA immune complex as a monitoring biomarker of response to telitacicept in IgA nephropathy. [PDF]

Front Immunol
Fu R, Gao J, Zhang Y, He Z, Du X.
europepmc   +1 more source

IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy. [PDF]

Diagnostics (Basel)
Alobaidi S.
europepmc   +1 more source

IgA Nephropathy in a Patient with Tularemia: Causality or Coincidental Association? [PDF]

Infect Dis Clin Microbiol
Çakır Kıymaz Y, Keskin E, Kaya Ş, Candan F.   +3 more
europepmc   +1 more source